

From: Tom McAllister <pharma@smiconferences.co.uk>
To: Kester, Tonykester@aging.sc.gov
Date: 4/25/2016 5:38:11 AM
Subject: Clinical Breakthroughs in Pain Therapy Unveiled by Pfizer, Regeneron, Imperial College London, Novartis and MSD USA at Pain Therapeutics 2016

The only event dedicated to accelerate your market access:

Pain Therapeutics 2016

16th Annual Conference: 23th & 24th May | Interactive Workshops: 25th May
Holiday Inn Kensington Forum, London UK

Proudly Sponsored by:

Collectricon AB, Centre for Human Drug Research, MD Biosciences and PRA Health Services

[Register](#) | [View Agenda](#) | [Get in Touch](#)

NEW SPONSOR:

PRA Health Services come on board as latest sponsors and will be speaking on experimental pain models in early phase drug development. Check out the [new presentation](#) from Project Manager, **Martin Harbers**.

ATTENDEE LIST RELEASED!

Chromocell Corporation, Korea Institute of Science & Technology, Biogen Idec Ltd and Glenmark Pharmaceuticals have just secured their places joining teams from GSK, Ethypharmrt, Reckitt Benckiser + more. Take a look at the [attendee list](#) in the event download center.

NEW INTERVIEW OUT TODAY!

Visit the [download centre](#) to read the new Q&A with **Novartis**.

A SPOTLIGHT ON CLINICAL BREAKTHROUGHS:

Pfizer, Regeneron, Imperial College London, Novartis and MSD USA unveil key breakthroughs in pain therapy.

Dear Mr Tony Kester,

As well as being supported by leading scientific experts in the area of neuropathic pain and featuring a panel of senior representatives from international pharmaceutical organisations, [Pain Therapeutics 2016](#) will include a dedicated spotlight on the latest **clinical breakthroughs** with *FIVE* exclusive presentations on key evolving therapies.

- 1. Voltage Gated Sodium Channels: New Pain Therapies Revealed**
Aoibhinn McDonnell, Clinician, Director, **Pfizer**
Receive new updates on the preclinical and clinical development of selective sodium channel blockers with results from the assessment of PF-05089771 in painful diabetic neuropathy.
- 2. Treatment of moderate to severe chronic pain**
Catherine Stehman-Breen, VP Clinical Sciences, **Regeneron Pharmaceuticals Inc**
Discuss the epidemiology of moderate to severe chronic pain and explore emerging new treatment options.
- 3. Small Fibre Neuropathy and Channelopathy: From Pain Relief to Disease Modification**
Praveen Anand, Professor of Neurology, **Imperial College London**
Discover advanced diagnostic techniques through case studies on clinical translation success in Phase II trials; and capsaicin 8% patch Qutenza for pain relief and disease modification.
- 4. A Novel Treatment Option for Neuropathic Pain**
Shaloo Pandhi, Global Program Medical Director, **Novartis**
Evidence of safety and analgesic action of EAM410 has been demonstrated in robust pre-clinical and classical clinical models of peripheral neuropathic pain. What are next steps in clinical development?

5. **Translational Assays: Supporting a Small Molecule Nav1.7 Inhibitor Program**

Andrea Houghton, Executive Director, **MSD, USA**

Learn how novel assays in vivo assays are used in the development of a small molecule Nav1.7 inhibitor. How can these assays be used in a phase 1 program?

[Download a brochure](#) to see the full speaker line-up or [scroll down for agenda highlights](#).

NOVARTIS INTERVIEW RELEASED:

Novartis Global Program Medical Director, **Shaloo Pandhi**, is responsible for clinical leadership of the development program for a novel molecule targeted for neuropathic pain treatment. In the run-up to her address we caught up with Shaloo to discuss current industry developments and her upcoming talk. Read the full Q&A in the event [download center](#).

JOIN YOUR PEERS AND GET INVOLVED:

HOW TO REGISTER:

Visit www.pain-therapeutics.co.uk

SPONSORSHIP INFORMATION:

For details on tailored sponsorship packages, contact Alia Malick on:
+44 (0) 207 827 6168 or email amalick@smi-online.co.uk

DELEGATE INFORMATION:

For delegate enquiries, pharma rates and group bookings, contact Matthew Apps on:
+44 (0) 20 7827 6093 or email mapps@smi-online.co.uk

AGENDA HIGHLIGHTS | [Download Brochure](#)

Day One - 23rd May 2016

Day Two - 24th May 2016

8.30 **Registration & Coffee**
 9.00 **Chairman's Opening Remarks**
Steven Kamerling, Therapeutic Area Head for Pain, Inflammation and Oncology, **Zoetis**
 9.10 **Pain Drug Discovery: Learnings over a Decade?**
Neelima Khairatkar Joshi, Sr Vice President, **Glenmark Pharmaceuticals**
 9.50 **Understanding ligand recognition on the molecular level**
Achim Kless, Associate Scientific Director, **Grunenthal GmbH**
 10.30 **Morning Coffee**
 11.00 **MDB010506: Discovery of a novel, highly effective small molecule compound for neuropathic pain; from phenotypic screening to full, preclinical lead validation**
Sigal Meilin, Scientific Director, **MD Biosciences**
 11.40 **Challenges and opportunities in topical ibuprofen development**
Ozgur Sancak, Global Medical Science Lead for Pain, **Reckitt Benckiser**
 12.20 **Networking Lunch**
 1.30 **Current questions to animal models of pain**
Thomas Christoph, Senior Director, Head of Pain Pharmacology, **Grunenthal GmbH**
 2.10 **Pain, Osteoarthritis & Translational Veterinary Medicine**
Steven Kamerling, Therapeutic Area Head for Pain, Inflammation and Oncology, **Zoetis**
 2.50 **Afternoon Tea**
 3.20 **Reproducibility of a battery of human evoked pain tests to determine the pharmacological profile of novel analgesic drugs**
Geert Jan Groeneveld, Research Director Neurology & Pain, **Centre for Human Drug Research**
 4.00 **Translational biomarker for studying target engagement of ion channels in peripheral nerve**
Martin Koltzenburg, Chair of Clinical Neurophysiology, **University College London**
 4.40 **Human Tissue in pain research**
Fiona Boissonade, Head of Neuroscience Research Group, **The University Of Sheffield**
 5.20 **Panel discussion: Medical incidents in an experimental drug trials**
Steven Kamerling, Therapeutic Area Head for Pain, Inflammation and Oncology, **Zoetis**
Fiona Boissonade, Head of Neuroscience Research Group, **The University Of Sheffield**
Thomas Christoph, Senior Director, Head of Pain Pharmacology, **Grunenthal GmbH**
Chao Chen, Therapy Area Head, **Glaxosmithkline**
Martin Koltzenburg, Chair of Clinical Neurophysiology, **University College London**
 6.00 **Chairman's Closing Remarks and Close of Day One**
Steven Kamerling, Therapeutic Area Head for Pain, Inflammation and Oncology, **Zoetis**

8.30 **Registration & Coffee**
 9.00 **Chairman's Opening Remarks**
Stephen Doberstein, Senior Vice President and Chief Scientific Officer, **Nektar Therapeutics**
 9.10 **NKTR-181, A Novel mu-opioid Analgesic Designed for Inherent Low Abuse Liability**
Stephen Doberstein, Senior Vice President and Chief Scientific Officer, **Nektar Therapeutics**
 9.50 **Strategies to minimise risk for opioid dependence**
Remigiusz Lecybyl, Consultant in Chronic Pain, **The Lewisham Hospital NHS Trust**
 10.30 **Morning Coffee**
 11.00 **Experimental pain models in early phase drug development**
Marten Harbers, Project Manager, **PRA Health Sciences**
 11.40 **Voltage gated sodium channels... new pain therapies**
Aoibhinn McDonnell, Clinician, Director, **Pfizer**
 12.20 **Treatment of moderate to severe chronic pain**
Catherine Stehman-Breen, VP Clinical Sciences, **Regeneron Pharmaceuticals Inc**
 1.00 **Networking Lunch**
 2.00 **Small fibre neuropathy and channelopathy: from pain relief to disease modification**
Praveen Anand, Professor of Neurology, **Imperial College London**
 2.40 **Design and Interpretation of Clinical Proof-of-Concept Trials for Pain Drugs**
Chao Chen, Therapy Area Head, **Glaxosmithkline**
 3.20 **Phenotypic Screening with iPSC-Sensory Neuron Excitability Assays**
Darren Cawkill, Head of Assay Development & Screening, **Pfizer**
 4.00 **Afternoon Tea**
 4.30 **EMA401- Novel treatment option for neuropathic pain**
Shaloo Pandhi, Global Program Medical Director, **Novartis**
 5.10 **Developing translational assays to support a small molecule Nav1.7 inhibitor program**
Andrea Houghton, Executive Director, **MSD, USA**
 5.50 **Chairman's Closing Remarks and Close of Day Two**
Stephen Doberstein, Senior Vice President and Chief Scientific Officer, **Nektar Therapeutics**

[Download](#) the brochure for a detailed agenda and don't forget to check out the two [interactive workshops](#) on **25th May**.

Proudly Sponsored by:

Register online at: www.pain-therapeutics.co.uk

You are registered as: kester@aging.sc.gov Your Unique Reference Number: 92804565
To update your contact preferences please go to <http://www.smi-online.co.uk/update-preferences>